We evaluated antibody against Epstein-Barr virus glycoproteins (gp350, gH/gL, gB, gp42) in 97 nasopharyngeal carcinoma (NPC) cases and 97 cancer-free controls. Each unit increase in log-transformed antibody against gp350 and gH/gL was associated with 2.27 (95% confidence interval [CI], 1.20-4.29) and 2.18 (95% CI, 1.22-3.90) higher odds of NPC, respectively. This association was more apparent for NPC diagnosed within 5 years of antibody measurement.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745775 | PMC |
| http://dx.doi.org/10.1093/ofid/ofac635 | DOI Listing |
Publication Analysis
Top Keywords
epstein-barr virus
8
nasopharyngeal carcinoma
8
gp350 gh/gl
8
virus glycoprotein
4
antibody
4
glycoprotein antibody
4
antibody titers
4
titers risk
4
risk nasopharyngeal
4
carcinoma evaluated
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!